AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31967515 — intervention group
Group type: COMPARATOR
Intervention: Control group (Remifentanil)
Number of subjects: 125
Study 31284424 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly fermented infant formula with 30% fermented formula and 0.8 g/100 mL scGOS/lcFOS
Number of subjects: 200
Study 31284424 — intervention group
Group type: COMPARATOR
Intervention: Non-fermented control infant formula without scGOS/lcFOS
Number of subjects: 200
Study 31284424 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly fermented infant formula with prebiotics
Number of subjects: 200
Study 31284424 — intervention group
Group type: EXPERIMENTAL
Intervention: Both study formulae
Number of subjects: 200
Study 31284424 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly fermented formula with prebiotics
Number of subjects: 200
Study 28893433 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - 3 cycles of 5-min inflation (300mmHg) and deflation on the left arm
Number of subjects: 72
Study 28893433 — intervention group
Group type: COMPARATOR
Intervention: Control - deflated cuff placement
Number of subjects: 72
Study 26153177 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational session about caring for patients with indwelling urinary catheters
Number of subjects: 0
Study 26153177 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational session)
Number of subjects: 0
Study 24766987 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation program (aerobic exercise at 70% to 85% of maximal heart rate for 3 sessions per week plus usual care)
Number of subjects: 96
Study 24766987 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 96
Study 23079125 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX 7.5‐20 mg/week + cyclosporine (CYA) 2.5‐4 mg/kg (combination)
Number of subjects: 160
Study 23079125 — intervention group
Group type: COMPARATOR
Intervention: MTX + placebo-CYA (monotherapy)
Number of subjects: 160
Study 20659915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg kg(‐1) (maximum 10 mg)
Number of subjects: 77
Study 20659915 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 77
Study 18796506 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based Chronic Disease Self-Management Program
Number of subjects: 415
Study 18796506 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 415
Study 16251562 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of 0.2% hypobaric tetracaine
Number of subjects: 60
Study 16251562 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg of 0.2% hypobaric tetracaine
Number of subjects: 60
Study 16251562 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 mg of 0.2% hypobaric tetracaine
Number of subjects: 60
Study 12087923 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of nifedipine in the test preparation 'XL' (Nifecard)
Number of subjects: 42
Study 12087923 — intervention group
Group type: COMPARATOR
Intervention: 30 mg of nifedipine in the reference formulation 'LA'
Number of subjects: 42
Study 10334239 — intervention group
Group type: EXPERIMENTAL
Intervention: Age groups (20-39, 40-59, 60-79, 80-100)
Number of subjects: 40
Study 8761190 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 10
Study 8761190 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 10
Study 1416009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprotte 24 G needle (n = 28)
Number of subjects: 56
Study 1416009 — intervention group
Group type: COMPARATOR
Intervention: Vygon 29 G needle (n = 28)
Number of subjects: 56
Study 1416009 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (n = 28)
Number of subjects: 56
Study 3890228 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (280 mg, single dose, intramuscularly)
Number of subjects: 415
Study 3890228 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanamycin (2 g, single dose, intramuscularly)
Number of subjects: 415
Study 31380887 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare system factors (identified through thematic analysis)
Number of subjects: 19
Study 30447669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 292
Study 30447669 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 292
Study 26978136 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial administration of 3 g of tranexamic acid (TXA)
Number of subjects: 200
Study 26978136 — intervention group
Group type: COMPARATOR
Intervention: Control group without TXA
Number of subjects: 200
Study 24650447 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 µg) plus Formoterol (12 µg)
Number of subjects: 167
Study 24650447 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 µg) plus Doxofylline (400 mg)
Number of subjects: 167
Study 24650447 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 µg) plus Montelukast (10 mg)
Number of subjects: 167
Study 24650447 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 µg) plus Tiotropium (18 µg)
Number of subjects: 167
Study 22810981 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation (1 mg/d)
Number of subjects: 276
Study 22810981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 20571496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(6) supplementation (100 mg/day) plus 5 mg/day folic acid
Number of subjects: 35
Study 20571496 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 mg/day folic acid only)
Number of subjects: 35
Study 18055960 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard intervention (plus treatment as usual)
Number of subjects: 0
Study 18055960 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 0
Study 16032446 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose buprenorphine (BH group)
Number of subjects: 50
Study 16032446 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose buprenorphine (BL group)
Number of subjects: 50
Study 16032446 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 11878654 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg)
Number of subjects: 41
Study 11878654 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 41
Study 11878654 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol + NSAID
Number of subjects: 41
Study 11878654 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs alone
Number of subjects: 41
Study 10438047 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-D vaccine
Number of subjects: 135
Study 10438047 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC vaccine
Number of subjects: 135
Study 10438047 — intervention group
Group type: EXPERIMENTAL
Intervention: HbNOMP vaccine
Number of subjects: 135
Study 10438047 — intervention group
Group type: EXPERIMENTAL
Intervention: All three vaccines
Number of subjects: 135
Study 7605834 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2341658 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical interferon alpha 2b gel (30 million IU/gm), applied 4 times a day for 4 weeks
Number of subjects: 24
Study 2341658 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation, applied 4 times a day for 4 weeks
Number of subjects: 24
Study 6989438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplements (ergocalciferol, 1000 IU/day)
Number of subjects: 126
Study 6989438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 31744313 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 96
Study 31744313 — intervention group
Group type: COMPARATOR
Intervention: Local Corticosteroid Injection (LCI)
Number of subjects: 96
Study 30655275 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxelotor 500-1000 mg per day
Number of subjects: 38
Study 30655275 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxelotor 700 or 900 mg per day
Number of subjects: 38
Study 30655275 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxelotor 900 mg per day for 6 months (extension study)
Number of subjects: 38
Study 30655275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 28581919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk fill resin composite (Tetric EvoCeram Bulk Fill [TB])
Number of subjects: 50
Study 28581919 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanofill resin composite (Filtek Ultimate [FU])
Number of subjects: 50
Study 28581919 — intervention group
Group type: COMPARATOR
Intervention: Both groups (TB and FU)
Number of subjects: 50
Study 26440636 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial exercise (E trial)
Number of subjects: 15
Study 26440636 — intervention group
Group type: COMPARATOR
Intervention: Control (C trial)
Number of subjects: 15
Study 23356886 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day regimen with high-dose PPI (lansoprazole 60 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 1 g once daily)
Number of subjects: 110
Study 23356886 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day regimen with high-dose PPI (lansoprazole 60 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 1 g once daily)
Number of subjects: 110
Study 20966907 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-only (PO) treatment
Number of subjects: 80
Study 20966907 — intervention group
Group type: COMPARATOR
Intervention: Parent + child (PC) treatment
Number of subjects: 80
Study 19943573 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 30
Study 19943573 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 30
Study 17354538 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 5000
Study 17354538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 5000
Study 17354538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study 14734329 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded activity
Number of subjects: 134
Study 14734329 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study 11517419 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutics for progressive multifocal leukoencephalopathy (PML)
Number of subjects: 0
Study 11517419 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratification
Number of subjects: 0
Study 11517419 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim analyses, toxicity management, validation of secondary clinical measures
Number of subjects: 0
Study 9681723 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation
Number of subjects: 14
Study 9681723 — intervention group
Group type: COMPARATOR
Intervention: Heparin anticoagulation
Number of subjects: 14
Study 8156447 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy with Dermatophagoides pteronyssinus at high doses
Number of subjects: 18
Study 8156447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3264709 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg‐1 for induction and maintenance with 70% nitrous oxide in oxygen
Number of subjects: 0
Study 3264709 — intervention group
Group type: COMPARATOR
Intervention: Thiamylal 4.0 mg kg‐1 for induction and maintenance with 70% nitrous oxide in oxygen
Number of subjects: 0
Study 31321928 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dose first (AB sequence)
Number of subjects: 60
Study 31321928 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dose first (BA sequence)
Number of subjects: 60
Study 27476354 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 1000
Study 27476354 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (Control)
Number of subjects: 1000
Study 26161657 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-Breastfeeding and Healthy Complementary Feeding Intervention
Number of subjects: 323
Study 26161657 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 323
Study 24391767 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-T horizontal open MR scanner
Number of subjects: 93
Study 24391767 — intervention group
Group type: COMPARATOR
Intervention: 1.5-T short-bore MR scanner
Number of subjects: 93
Study 20721883 — intervention group
Group type: EXPERIMENTAL
Intervention: Taribavirin (TBV) 20 mg/kg/day
Number of subjects: 278
Study 20721883 — intervention group
Group type: EXPERIMENTAL
Intervention: Taribavirin (TBV) 25 mg/kg/day
Number of subjects: 278
Study 20721883 — intervention group
Group type: EXPERIMENTAL
Intervention: Taribavirin (TBV) 30 mg/kg/day
Number of subjects: 278
Study 20721883 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin (RBV) 800-1400 mg/day
Number of subjects: 278
Study 18279048 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 2
Study 18279048 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 2
Study 15841403 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic curettes and rinsing with chlorhexidine digluconate (P)
Number of subjects: 80
Study 15841403 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic system (U)
Number of subjects: 80
Study 15841403 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (Y)
Number of subjects: 80
Study 15841403 — intervention group
Group type: COMPARATOR
Intervention: Unworn titanium discs (C)
Number of subjects: 80
Study 12578927 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar NC test with cut-off value of 0.5 msec; sensitivity 64.0%
Number of subjects: 225
Study 12578927 — intervention group
Group type: EXPERIMENTAL
Intervention: D4 NC test with cut-off value of 0.7 msec; sensitivity 71.2%
Number of subjects: 225
Study 12578927 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 NC test with cut-off value of 44 m/sec; sensitivity 44.8%
Number of subjects: 225
Study 12578927 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar NC test with cut-off value of 0.4 msec; sensitivity for pretest probabilities >or=75%
Number of subjects: 225
Study 12578927 — intervention group
Group type: EXPERIMENTAL
Intervention: D4 NC test with cut-off value of 0.5 msec; sensitivity for pretest probabilities >or=75%
Number of subjects: 225
Study 12578927 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 NC test with cut-off value of 48 m/sec; sensitivity for pretest probabilities >or=75%
Number of subjects: 225
Study 12578927 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal test values; pretest probabilities <25%
Number of subjects: 225
Study 12578927 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid cut-off values; sensitivity <95%
Number of subjects: 225
Study 10540659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cragg thrombolytic brush catheter
Number of subjects: 77
Study 10540659 — intervention group
Group type: COMPARATOR
Intervention: Pulsed spray
Number of subjects: 77
Study 10540659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 77
Study 9005788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once a day for 7 to 14 days (average 11 days), administered intravenously for the first 3-5 days and then orally
Number of subjects: 15
Study 2007937 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic surfactant treatment
Number of subjects: 246
Study 2007937 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue surfactant treatment
Number of subjects: 246
Study 2007937 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 246
Study 2007937 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant treatment (both prophylactic and rescue)
Number of subjects: 246
Study 369009 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine irrigation (0.1% available iodine)
Number of subjects: 168
Study 369009 — intervention group
Group type: COMPARATOR
Intervention: Saline solution irrigation (Control)
Number of subjects: 168
Study 30786157 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 0.075 mg/kg (maximum 5 mg)
Number of subjects: 9
Study 30786157 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 0.15 mg/kg (maximum 10 mg)
Number of subjects: 9
Study 30786157 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 0.3 mg/kg (maximum 20 mg)
Number of subjects: 9
Study 30786157 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (all dose levels)
Number of subjects: 9
Study 30786157 — intervention group
Group type: COMPARATOR
Intervention: Concomitant chemotherapy
Number of subjects: 9
Study 28575414 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (L-AMB) at 5 mg/kg intravenously, twice weekly
Number of subjects: 355
Study 28575414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 25740641 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless hands-free surgical pointer (WHaSP)
Number of subjects: 103
Study 25740641 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods (without WHaSP)
Number of subjects: 103
Study 23636036 — intervention group
Group type: EXPERIMENTAL
Intervention: Perennial immunotherapy (PIT)
Number of subjects: 120
Study 23636036 — intervention group
Group type: COMPARATOR
Intervention: Preseasonal immunotherapy (PSIT)
Number of subjects: 120
Study 19684411 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐KW/R‐BW ratio <or=4.25
Number of subjects: 44
Study 19684411 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐FRV/R‐BW ratio <or=5.14
Number of subjects: 44
Study 19684411 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐SKGFR/R‐BW ratio <or=1.06
Number of subjects: 44
Study 19684411 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐FRV
Number of subjects: 44
Study 19684411 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor age
Number of subjects: 44
Study 17335562 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model including standard clinical signs and symptoms (fever, cough, sputum production, abnormal chest auscultation, dyspnea)
Number of subjects: 545
Study 17335562 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model including PCT and hsCRP
Number of subjects: 545
Study 17335562 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 545
Study 17335562 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly sensitive C-reactive protein (hsCRP)
Number of subjects: 545
Study 17335562 — intervention group
Group type: EXPERIMENTAL
Intervention: Total leukocyte count
Number of subjects: 545
Study 17335562 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) for predicting bacteremia
Number of subjects: 545
Study 15082209 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stage implant
Number of subjects: 42
Study 15082209 — intervention group
Group type: COMPARATOR
Intervention: 1-stage implant
Number of subjects: 42
Study 15082209 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 42
Study 11174430 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent harmonic imaging (IHI)
Number of subjects: 12
Study 11174430 — intervention group
Group type: COMPARATOR
Intervention: Intermittent fundamental imaging
Number of subjects: 12
Study 11174430 — intervention group
Group type: EXPERIMENTAL
Intervention: Videodensitometry
Number of subjects: 12
Study 9924848 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin/N-acetylcysteine (NTG/NAC)
Number of subjects: 69
Study 9924848 — intervention group
Group type: COMPARATOR
Intervention: Furosemide/morphine
Number of subjects: 69
Study 9924848 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 69
Study 7999403 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-emetic treatment (specifics not provided)
Number of subjects: 0
Study 7999403 — intervention group
Group type: COMPARATOR
Intervention: Nurses' assessment
Number of subjects: 0
Study 7999403 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' assessment
Number of subjects: 0
Study 3186615 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg sustained release tablets once daily
Number of subjects: 12
Study 3186615 — intervention group
Group type: COMPARATOR
Intervention: Verapamil 120 mg conventional tablets administered twice daily
Number of subjects: 12
Study 29562260 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist trigger followed by specialized regimen (1500 IU hCG) at time of oocyte retrieval plus oral estradiol and intramuscular progesterone during luteal phase
Number of subjects: 190
Study 29562260 — intervention group
Group type: COMPARATOR
Intervention: hCG trigger (5000 IU) with luteal support (oral estradiol and vaginal progesterone)
Number of subjects: 190
Study 28252533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based chemotherapy (arm A)
Number of subjects: 1603
Study 28252533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based chemotherapy plus cetuximab (arm B)
Number of subjects: 1603
Study 28252533 — intervention group
Group type: COMPARATOR
Intervention: dNLR < 2.2
Number of subjects: 1603
Study 25466953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice (330 ml/d) for 20 days
Number of subjects: 64
Study 25466953 — intervention group
Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 64
Study 22586252 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 56
Study 22586252 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (AE)
Number of subjects: 56
Study 21467190 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50, 100, 200, and 400 mg)
Number of subjects: 8
Study 21467190 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (4 and 8 mg)
Number of subjects: 8
Study 21467190 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (30 and 60 mg)
Number of subjects: 8
Study 21467190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 18308793 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 46